Background. An important feature of Cryptococcus neoformans (CN) is an ability to undergo morphological changes that enhance virulence and development of cryptococcal disease (CD). CN can change its size by capsule enlargement alone or capsule and cell body enlargement, resulting in "titan cells. " Titan cells enable CN to evade host defense mechanisms. Human and mouse β-glucan antibodies bind and inhibit CN growth in vitro. Naturally occurring antibodies in human serum bind β-glucans. In this study, we determined the effect of human IgM and IgG on CN size and titan cell formation in vitro.
Detection of Blastomyces dermatitidis Antigen in Urine Using a Novel
Methods. Clinical residual urine specimens collected from 86 unique patients with a previously negative (n = 63) or positive (n = 23) result by the MVDx Blastomyces Ag Quantitative EIA were evaluated by the Aliquot BdAg ELISA. Clinical information was available for five of these patients. In addition, analytical specificity was evaluated using 15 residual urine samples positive for Streptococcus pneumoniae (n = 5), Legionella pneumophila (n = 5) or Histoplasma capsulatum (n = 5) antigens.
Results. The Aliquot BdAg ELISA showed 95.7% (22/23), 96.8% (61/63) and 96.5% (83/86) positive, negative and overall agreement with the MVDx BdAg EIA, respectively. Seventeen of the 22 samples positive for BdAg by both assays resulted positive by a H. capsulatum antigen ELISA (IMMY, Norton, OK). Of the five well-characterized patients, one was diagnosed with blastomycosis based on a positive B. dermatitidis immunodiffusion result; this patient was positive by both BdAg assays. All urine samples positive for S. pneumoniae or L. pneumophila antigen were negative by the Aliquot BdAg ELISA, while all five samples positive by the IMMY H. capsulatum urine antigen ELISA were also positive by the Aliquot BdAg assay.
Conclusion. The Aliquot BdAg ELISA demonstrated excellent agreement with the MVDx BdAg EIA. Cross-reactivity between B. dermatitidis and H. capsulatum antigen detection assays has been previously established and is a notable limitation to the Aliquot BdAg assay. Further evaluation of this assay using specimens from well-characterized patients with and without blastomycosis is warranted.
Disclosures. All authors: No reported disclosures. Methods. We measured levels of BDG in paired plasma and CSF samples, and compared levels with GDS, soluble urokinase plasminogen activator receptor (suPAR; a marker of monocyte activation and chronic inflammation that has previously been associated with non-AIDS disorders) and plasma CD4/CD8 ratio in a cohort of 61 HIV+ adults on suppressive ART. Study samples were collected as part of the prospective CHARTER study between 2005 and 2015 at the University of California San Diego and were stored at −80°C on the day of collection. BDG testing of blood plasma and CSF supernatant was performed at the Associates of Cape Cod, Inc., research laboratories using the Fungitell assay.
Plasma (1→3)-β-D-Glucan Levels
Results. Median plasma BDG level was 18 pg/mL (range: 2-60 pg/mL), median CSF BDG level was 20 pg/mL (range: 0-830 pg/mL). Higher levels of plasma BDG were associated with more severe cognitive impairment as measured by the GDS (Spearman r = 0.35; P = 0.006, Figure) . Individuals with neurocognitive impairment (i.e., GDS > 0.5, n = 33) had higher plasma BDG levels compared with unimpaired individuals (P = 0.027). Plasma levels of BDG and suPAR correlated significantly (r = 0.31, P = 0.016), while all other correlations were nonsignificant (e.g., CSF BDG and GDS Conclusion. Elevated plasma levels of BDG may be an indicator of gut barrier integrity failure and an independent biomarker associated with neurocognitive functioning in HIV+ adults on suppressive ART.
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